CN102164884B - 羟基丁酸酯及其医学用途 - Google Patents

羟基丁酸酯及其医学用途 Download PDF

Info

Publication number
CN102164884B
CN102164884B CN200980136723.1A CN200980136723A CN102164884B CN 102164884 B CN102164884 B CN 102164884B CN 200980136723 A CN200980136723 A CN 200980136723A CN 102164884 B CN102164884 B CN 102164884B
Authority
CN
China
Prior art keywords
compound
hydroxybutyl
hydroxybutyrate
treatment
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980136723.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102164884A (zh
Inventor
K·克拉克
R·L·韦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GVMT OF USA AS REPRESENTED
Oxford Science And Technology Innovation Co Ltd, University of
Original Assignee
Oxford University Innovation Ltd
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd, United States Department of Health and Human Services filed Critical Oxford University Innovation Ltd
Publication of CN102164884A publication Critical patent/CN102164884A/zh
Application granted granted Critical
Publication of CN102164884B publication Critical patent/CN102164884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200980136723.1A 2008-08-21 2009-04-16 羟基丁酸酯及其医学用途 Active CN102164884B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9075108P 2008-08-21 2008-08-21
US61/090,751 2008-08-21
PCT/US2009/040766 WO2010021766A1 (en) 2008-08-21 2009-04-16 Hydroxybutyrate ester and medical use thereof

Publications (2)

Publication Number Publication Date
CN102164884A CN102164884A (zh) 2011-08-24
CN102164884B true CN102164884B (zh) 2015-03-11

Family

ID=40885956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980136723.1A Active CN102164884B (zh) 2008-08-21 2009-04-16 羟基丁酸酯及其医学用途

Country Status (10)

Country Link
EP (3) EP3296284B1 (cg-RX-API-DMAC10.html)
JP (2) JP5773870B2 (cg-RX-API-DMAC10.html)
CN (1) CN102164884B (cg-RX-API-DMAC10.html)
AU (1) AU2009283171B2 (cg-RX-API-DMAC10.html)
CA (1) CA2734720C (cg-RX-API-DMAC10.html)
DK (2) DK2328858T3 (cg-RX-API-DMAC10.html)
ES (2) ES2655367T3 (cg-RX-API-DMAC10.html)
NO (1) NO2328858T3 (cg-RX-API-DMAC10.html)
PL (2) PL2328858T3 (cg-RX-API-DMAC10.html)
WO (1) WO2010021766A1 (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
WO2009089144A1 (en) 2008-01-04 2009-07-16 Isis Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) * 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) * 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
CA2973342A1 (en) * 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
CN103860533A (zh) * 2014-02-12 2014-06-18 新乡医学院 β羟基丁酸在治疗帕金森病中的应用
WO2015140752A1 (en) * 2014-03-19 2015-09-24 Stellenbosch University Method for treating or enhancing muscle tissue
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
MX390420B (es) * 2016-12-23 2025-03-20 Univ Leuven Kath 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos.
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
BR112020001285A2 (pt) * 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
GB201715654D0 (en) * 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
GB2575623B (en) * 2018-06-04 2022-10-26 Tdeltas Ltd 3-hydroxybutyrate esters for treating cancer cachexia
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
BR112020023132A2 (pt) 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
GB2577723A (en) * 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
WO2020147979A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von hydroxycarbonsäuren
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
AU2020274805A1 (en) 2019-05-10 2021-10-28 Ketoswiss Ag Ketone bodies enclosed in microbeads
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CA3135099A1 (en) * 2019-05-21 2020-11-26 Societe Des Produits Nestle S.A. Dietary butyrate
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
ES2969217T3 (es) * 2019-06-12 2024-05-17 Ketolipix Therapeutics Gmbh Procedimiento para la producción de ésteres a base de poliol, en particular ésteres de poliglicerol, de ácidos hidroxicarboxílicos
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
WO2021195477A1 (en) * 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
WO2021231271A1 (en) * 2020-05-12 2021-11-18 Genomatica, Inc. Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
EP4146339B1 (de) * 2020-07-13 2024-04-10 KetoLipix Therapeutics GmbH Oxobutanol-ester von polymeren carbonsäuren und deren herstellung
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113045416B (zh) * 2021-03-23 2023-08-18 南京纽邦生物科技有限公司 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20250275986A1 (en) 2021-07-17 2025-09-04 Ketoswiss Ag Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524611A (en) * 1975-01-07 1978-09-13 Basf Ag 1,3-butanediol mono - (3' -hydroxybutyrates) and process for their manufacture
US5112865A (en) * 1987-11-19 1992-05-12 Solvay & Cie (Societe Anonyme) Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2007063037A2 (de) * 2005-11-29 2007-06-07 Basf Se Verfahren zur um- oder veresterung von seitenketten in polymeren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0755158B2 (ja) * 1986-10-30 1995-06-14 チッソ株式会社 光学活性エステルの製造法
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
ES2574918T3 (es) 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
US8452351B2 (en) * 2008-06-02 2013-05-28 Qualcomm Incorporated Methods and apparatus for saving battery power in mobile stations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524611A (en) * 1975-01-07 1978-09-13 Basf Ag 1,3-butanediol mono - (3' -hydroxybutyrates) and process for their manufacture
US5112865A (en) * 1987-11-19 1992-05-12 Solvay & Cie (Societe Anonyme) Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2007063037A2 (de) * 2005-11-29 2007-06-07 Basf Se Verfahren zur um- oder veresterung von seitenketten in polymeren

Also Published As

Publication number Publication date
EP4011374A1 (en) 2022-06-15
EP3296284B1 (en) 2021-12-01
AU2009283171B2 (en) 2014-08-14
PL2328858T3 (pl) 2018-06-29
CA2734720C (en) 2017-07-18
JP2015057427A (ja) 2015-03-26
ES2907630T3 (es) 2022-04-25
JP5773870B2 (ja) 2015-09-02
JP2012500264A (ja) 2012-01-05
CN102164884A (zh) 2011-08-24
PL3296284T3 (pl) 2022-06-13
EP2328858B1 (en) 2017-10-11
DK3296284T3 (da) 2022-02-28
EP3296284A1 (en) 2018-03-21
AU2009283171A1 (en) 2010-02-25
CA2734720A1 (en) 2010-02-25
HK1159604A1 (en) 2012-08-03
EP2328858A1 (en) 2011-06-08
ES2655367T3 (es) 2018-02-19
WO2010021766A1 (en) 2010-02-25
JP6092836B2 (ja) 2017-03-08
DK2328858T3 (en) 2018-01-15
NO2328858T3 (cg-RX-API-DMAC10.html) 2018-03-10

Similar Documents

Publication Publication Date Title
EP2328858B1 (en) Drink comprising hydroxybutyrate ester and medical use thereof
US10051880B2 (en) Hydroxybutyrate ester and medical use thereof
JP2023120442A (ja) 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物
JP5587780B2 (ja) フコキサンチン又はこれを含有する海藻類抽出物を含有する脂質代謝性疾患の予防又は治療用組成物
JP5300167B2 (ja) 気分障害治療用組成物
JP2008297209A (ja) 脂質代謝改善組成物
US20140378543A1 (en) Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances
JP2021501119A (ja) 丹参抽出物を含む内臓脂肪型肥満予防、改善又は治療組成物
JPH01294631A (ja) 糖尿性疾患治療予防剤及び飲食、し好物
US20190119705A1 (en) Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
JP2008255040A (ja) アディポネクチン産生促進剤
EP3801490A1 (en) Compounds for use in cancer cachexia
JP2008143811A (ja) 脂質代謝促進組成物
JP4560864B2 (ja) 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料
CA2459240C (en) Pharmaceutical composition for treating mood disorders
HK1159604B (en) Hydroxybutyrate ester and medical use thereof
JP2021016363A (ja) 脂質分解促進剤及びこれを含む飲食品、並びに脂質分解促進用加工食品
JP2023173641A (ja) 内臓脂肪低減剤およびその用途
JP6470879B1 (ja) 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物
JP2007246478A (ja) アセトアルデヒド代謝促進剤
JP2011051952A (ja) 皮膚角質層水分量の増加用組成物およびその経口摂取用製剤
JP2004307425A (ja) 抗ストレス剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159604

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1159604

Country of ref document: HK

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: oxford

Patentee after: University of Oxford science and Technology Innovation Co., Ltd.

Patentee after: Gvmt of The USA. As Represented

Address before: oxford

Patentee before: Isis Innovation Ltd.

Patentee before: Gvmt of The USA. As Represented